Samsung C&T (028260) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
10 Mar, 2026Executive summary
2Q24 consolidated sales reached KRW 11,005 bn, up KRW 419 bn year-over-year and KRW 209 bn quarter-over-quarter.
Operating profit for 2Q24 was KRW 900 bn, up KRW 188 bn from 1Q24 and KRW 128 bn from 2Q23.
Net profit for 2Q24 was KRW 734 bn, a decrease of KRW 88 bn quarter-over-quarter but up KRW 39 bn year-over-year.
Financial highlights
Gross profit for 2Q24 was KRW 1,913 bn, up KRW 264 bn quarter-over-quarter and KRW 225 bn year-over-year.
Operating margin improved to 8.2% in 2Q24 from 6.6% in 1Q24 and 7.3% in 2Q23.
1H24 sales totaled KRW 21,801 bn, up KRW 976 bn year-over-year; 1H24 net profit was KRW 1,556 bn, up KRW 109 bn.
Outlook and guidance
Continued focus on new business development in hydrogen, SMR, and bio sectors to drive future growth.
Expansion of food service and distribution business in Vietnam, leveraging new logistics infrastructure.
Latest events from Samsung C&T
- 3Q24 profit declined year-over-year, but F&B and bio segments showed strong growth.028260
Q3 202410 Mar 2026 - Net profit rose 15% year-over-year in 4Q 2024, driven by Bio and T&I growth.028260
Q4 202410 Mar 2026 - Net profit rose 14% year-over-year as Bio and T&I growth offset declines in other segments.028260
Q1 202510 Mar 2026 - Sequential sales and operating profit rose, but net profit fell; Bio outlook upgraded.028260
Q2 202510 Mar 2026 - Operating profit and net profit surged YoY, driven by Bio and F&B, with robust new orders.028260
Q3 202510 Mar 2026 - Net profit surged YoY in 4Q25, with Bio and E&C driving growth and a positive 2026 outlook.028260
Q4 202510 Mar 2026